Brazilian Pharmaceutical Company to Apply for Emergency Use of Russian Sputnik V Vaccine

The Russian laboratory has also announced an agreement to deliver ten million doses of the Sputinik V vaccine to Brazil by March.

RIO DE JANEIRO, BRAZIL - On Wednesday, January 13th, União Química pharmaceutical company and the Russian Direct Investment Fund (RDIF) announced they will apply for emergency use authorization of the Russian Sputnik V vaccine to the National Health Regulatory Agency (ANVISA) later this week, according to a statement released by the RDIF.

However, the vaccine's clinical trials need to be in phase 3 for the application to be possible. Last Friday, January 8th, ANVISA published a note explaining that União Química "requested authorization to conduct phase 3 clinical trials in Brazil" on December 29th, 2020, but . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?